Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting

APIActive Pharmaceutical Ingredients

Cardiovascular API

Cardiovascular API

Cardiovascular API

Cardiovascular API

Get access to Dr. Reddys largest Cardiovascular API portfolios to support your formulation success.

Dr. Reddy's offers a wide selection of cardiovascular active pharmaceutical ingredients used in the production of formulations to treat cardiovascular diseases. Our portfolio includes a broad class of cardiovascular molecules: HMG–CoA reductase inhibitors (statins), adenosine triphosphate-citrate lyase (ACL) inhibitors, calcium channel blockers, angiotensin II receptor antagonists, anticoagulants, beta-blockers, lipid modifiers, and others.
Dr. Reddy's is well-positioned to meet the global demands of Cardiovascular APIs. As a Cardiovascular API manufacturer and supplier, we follow a multistage synthesis to ensure supply chain sustainability and compliance with global regulatory requirements. In addition, Dr. Reddy's has established solid strategic sourcing, logistics partnerships and works closely with our customers to successfully manage the capacities of our manufacturing units ahead of launches.
Look at Dr. Reddy's broad selection of active pharmaceutical ingredients cardiovascular drugs used to treat cardiovascular diseases like hypertension, angina, benign prostate hyperplasia, pulmonary arterial hypertension, heredity angioedema, and many more.

Anti-hypertensives

Anti-hypertensives - Dr. Reddy’s

*Countries referred in the above graphic denotes DMF filing geographies

Anti-platelet

Anti-platelet - Dr. Reddy’s

*Countries referred in the above graphic denotes DMF filing geographies

Anti-anemic

Anti-anemic - Dr. Reddy’s

*Countries referred in the above graphic denotes DMF filing geographies

Anti-coagulants

Anti-coagulants - Dr. Reddy’s

*Countries referred in the above graphic denotes DMF filing geographies

Pulmonary arterial hypertension (PAH)

Pulmonary arterial hypertension (PAH) - Dr. Reddy’s

*Countries referred in the above graphic denotes DMF filing geographies

Lipid modifying agents

Lipid modifying agents - Dr. Reddy’s

*Countries referred in the above graphic denotes DMF filing geographies

Anti-Angina

Anti-Angina - Dr. Reddy’s

*Countries referred in the above graphic denotes DMF filing geographies

Hereditary Angioedema

Hereditary Angioedema - Dr. Reddy’s

*Countries referred in the above graphic denotes DMF filing geographies

Cardiovascular (transthyretin amyloidosis with polyneuropathy)

Cardiovascular (transthyretin amyloidosis with polyneuropathy) - Dr. Reddy’s

*Countries referred in the above graphic denotes DMF filing geographies

USPs of Cardiovascular API

Well-controlled impurity profile (APIs meets current and future stringent impurity limits).
Improved API flow property through controlled crystallization and process modifications to ease formulation development.
Completely backward integrated on the KSMs to ensure uninterrupted supplies.
Robust and sustainable supply chain.
Eligible to file DMF’s globally in all the markets.
Comprehensive assessment of synthetic routes and all toxicological attributes.
All GTIs are controlled below TTC limits.
Robust advanced analytical techniques to detect potential nitrosamine impurities.
Process development through QBD approach.
Customized particle sizes (PSD) to meet formulation requirements.
Successful BE/dossier filing record of accomplishment in the markets.
Multiple synthetic steps manufactured in-house.
API and KSM process with no IP Issues.
Comprehensive assessment of synthetic routes and all toxicological attributes.

Cardiovascular Products

Amlodipine Besylate

Therapy Area
Cardiovascular

Know More Enquire Now

Atorvastatin Calcium (Amorphous And Form 1)

Therapy Area
Cardiovascular

Know More Enquire Now

Bempedoic Acid

Therapy Area
Cardiovascular

Know More Enquire Now

Clopidogrel Bisulfate (Form 1)

Therapy Area
Cardiovascular

Know More Enquire Now

Clopidogrel Bisulfate (Form 2)

Therapy Area
Cardiovascular

Know More Enquire Now

Dabigatran Etexilate Mesylate

Therapy Area
Cardiovascular

Know More Enquire Now

Daprodustat

Therapy Area
Cardiovascular

Know More Enquire Now

Edoxaban

Therapy Area
Cardiovascular

Know More Enquire Now

Enalapril Maleate

Therapy Area
Cardiovascular

Know More Enquire Now

Ferric Maltol

Therapy Area
Cardiovascular

Know More Enquire Now

Finerenone

Therapy Area
Cardiovascular

Know More Enquire Now

Fondaparinux Sodium

Therapy Area
Cardiovascular

Know More Enquire Now

Irbesartan

Therapy Area
Cardiovascular

Know More Enquire Now

Iron Sucrose (Available For Selected Markets)

Therapy Area
Cardiovascular

Know More Enquire Now

Lacidipine

Therapy Area
Cardiovascular

Know More Enquire Now

Losartan Potassium

Therapy Area
Cardiovascular

Know More Enquire Now

Mavacamten

Therapy Area
Cardiovascular

Know More Enquire Now

Metoprolol Succinate

Therapy Area
Cardiovascular

Know More Enquire Now

Ramipril

Therapy Area
Cardiovascular

Know More Enquire Now

Ranolazine

Therapy Area
Cardiovascular

Know More Enquire Now

Rivaroxaban

Therapy Area
Cardiovascular

Know More Enquire Now

Roxadustat

Therapy Area
Cardiovascular

Know More Enquire Now

Sacubitril / Valsartan

Therapy Area
Cardiovascular

Know More Enquire Now

Tafamidis Meglumine

Therapy Area
Cardiovascular

Know More Enquire Now

Ticagrelor

Therapy Area
Cardiovascular

Know More Enquire Now

Treprostinil

Therapy Area
Cardiovascular

Know More Enquire Now

Treprostinil Olamine

Therapy Area
Cardiovascular

Know More Enquire Now

Valsartan

Therapy Area
Cardiovascular

Know More Enquire Now

Explore other Therapeutic categories.

FAQs

Our portfolio includes a broad class of cardiovascular molecules:

HMG–CoA reductase inhibitors (statins)
Adenosine triphosphate-citrate lyase (ACL) inhibitors
Calcium channel blockers
Angiotensin II receptor antagonists
Anticoagulants
Beta-blockers
Others

The global cardiovascular drugs market size is projected to hit around USD 231.7 billion by 2030 from valued at USD 155.6 billion in 2021 and growing at a CAGR of 4.52% from 2022 and 2030.

The global cardiovascular drugs market size is projected to hit around USD 231.7 billion by 2030 from valued at USD 155.6 billion in 2021 and growing at a CAGR of 4.52% from 2022 and 2030.

HMG–CoA inhibitors - decrease cholesterol levels. ACL Inhibitors - Direct inhibition of ACL by ETC-1002 lowers cytosolic acetyl CoA. Calcium channel blockers - prevent calcium from entering the cells of the heart & arteries. Angiotensin ii receptor antagonists - help relax veins & arteries to lower BP & make it easier for your heart to pump blood.

A control strategy has been defined using the QbD approach at every synthesis step and ensures that Dr. Reddy's APIs are free from potential genotoxic and carcinogenic impurities

Dr. Reddy's is well-positioned to meet the global demands of Cardiovascular APIs. We follow a multistage synthesis to ensure supply chain sustainability and compliance with global regulatory requirements. We established solid strategic sourcing and logistics partnerships and work closely with our customers to successfully manage the capacities of our manufacturing units ahead of launches.

Used to treat or improve symptoms of cardiovascular conditions including high blood pressure and heart failure.

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.

Have you booked your
CPHI Japan meeting slot yet?

Join us at booth: 5N-12

17th-19th April 2024

East Halls 4, 5 & 6, Tokyo Big Sight, Tokyo, Japan

Schedule a meeting